Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darrell R Fisher

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Nuclear Medicine and Biology|May 15, 2016
Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primatesBenjamin B Kasten, Michael T Azure, Trenton R Schoeb, et al.
Molecular Pharmaceutics|July 8, 2024
Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties of <sup>177</sup>Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating Hormone PeptidesZheng Qiao, Jingli Xu, Fabio Gallazzi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphomaGary L Griffiths, Serengulam V Govindan, Robert M Sharkey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2005
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptideYun Wu, Xianzhong Zhang, Zhengming Xiong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumesJoseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.
Pharmaceutics|July 21, 2019
Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177LutetiumKevin J H Allen, Rubin Jiao, Mackenzie E Malo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 17, 2008
203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detectionYubin Miao, Said D Figueroa, Darrell R Fisher, et al.
Physics in Medicine and Biology|July 25, 2024
Monte Carlo dosimetric analyses on the use of<sup>90</sup>Y-IsoPet intratumoral therapy in canine subjectsMislav Bobić, Carlos Huesa-Berral, Jack F Terry, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 27, 2014
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumabRuby Meredith, Julien Torgue, Sui Shen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Nuclear Medicine and Biology|May 15, 2016
Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primatesBenjamin B Kasten, Michael T Azure, Trenton R Schoeb, et al.
Molecular Pharmaceutics|July 8, 2024
Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties of <sup>177</sup>Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating Hormone PeptidesZheng Qiao, Jingli Xu, Fabio Gallazzi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphomaGary L Griffiths, Serengulam V Govindan, Robert M Sharkey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2005
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptideYun Wu, Xianzhong Zhang, Zhengming Xiong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumesJoseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.
Pharmaceutics|July 21, 2019
Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177LutetiumKevin J H Allen, Rubin Jiao, Mackenzie E Malo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 17, 2008
203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detectionYubin Miao, Said D Figueroa, Darrell R Fisher, et al.
Physics in Medicine and Biology|July 25, 2024
Monte Carlo dosimetric analyses on the use of<sup>90</sup>Y-IsoPet intratumoral therapy in canine subjectsMislav Bobić, Carlos Huesa-Berral, Jack F Terry, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 27, 2014
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumabRuby Meredith, Julien Torgue, Sui Shen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Pageof 9